Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States
John W. Ostrominski(Brigham and Women's Hospital), Elisabetta Patorno(Brigham and Women's Hospital), Janinne Ortega-Montiel(Brigham and Women's Hospital), Helen Tesfaye(Brigham and Women's Hospital), Deborah J. Wexler(Brigham and Women's Hospital), Sara J. Cromer(Harvard University), Julie M. Paik(Brigham and Women's Hospital), Elyse DiCesare(Brigham and Women's Hospital), CAROLINE ALIX(Brigham and Women's Hospital)
Cited by 18
Related Papers
The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults
|The Lancet Healthy Longevity|2021|264
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
|JAMA Cardiology|2023|248
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
|Annals of Internal Medicine|2019|215